Kornimate/medical-research-clean huggingface dataset:
competitive swimming and shoulder adaptations: the role of stroke specialty in adolescent swimmers

Conditions: Swimming; Shoulder; Adolescent

Summary: objectives: to examine the sport-specific adaptations and investigate the effect of swimming stroke specialization in shoulder complex among adolescent competitive swimmers. design: observational study. setting: athletic facilities. participants: a total of 76 adolescents participated including n = 28 non-swimmers as control group (cg) and n = 48 competitive swimmers as swimmers group (swg). main outcome measures: strength of glenohumeral (gh) and scapular muscles (sm), mobility of gh (gh roms) joint, proprioception, pectoralis minor length (pml), posterior shoulder tightness (pst) were evaluated for all participants. kerlan jobe orthopaedic score (kjoc) was sed to evaluate for swg. the tested shoulder physical performance parameters were compared between the groups.


Eligibility criteria:
inclusion criteria for swimmer group: * aged between 13 to 18 years * the asymptomatic swimmers with no history of major upper limb injury or surgery and no injury history of upper limb in last 6 months * having experience in at least 5 years competitive swimming, * actively participating in competitive swimming at least 1 year, * competing at least in national level and having swimming stroke specialization in competitive swimming inclusion criteria for control group: * aged between 13 to 18 years, * no competed in overhead sports like swimming, basketball, volleyball, tennis, baseball as professional or recreational, * no history of major upper limb injury or surgery in last 6 months. exclusion criteria for all participants: * if they had at least two positive signs by shoulder screening tests (hawkin's/kennedy subacromial impingement test, jobe/empty can test, external rotation resistance test, apprehension instability test, speed test and gerber lift-off test), * a bmi of 30 kg/m² or greater than 30 kg/m², * competing in paralympic sports, * if they had any major upper limb injuries or surgeries, * if they had any systemic, neurological or rheumatological diseases, * being pre-pubertal stage (tanner i) according to tanner scale, * indicated their unwillingness to participate to this study.

Keywords: swimming shoulder adolescent musculoskeletal screening
steroids pharmacokinetics and the response to prednisone therapy in giant cell arteritis

Conditions: Giant Cell Arteritis

Summary: the factors underlying the large interindividual variability in response to glucocorticoids in giant cell arteritis are poorly understood. the investigators hypothesize that a part of this variability is related to pharmacokinetic factors determined by genetic polymorphism: hepatic clearance involving cytochromes p450 of the subfamily 3a (cyp3a) and drug efflux leukocyte conditioned by p-glycoprotein involved in multidrug resistance drugs (abcb1). the investigators have designed a multicentric prospective pharmacokinetical and pharmacogenetic cohort study to assess the link between prednisolone clearance and the relapse risk in giant cell arteritis.


Eligibility criteria:
inclusion criteria: * diagnosis of gca, meeting at least 3 of the following 5 american college of rheumatology (acr) criteria for the diagnosis of gca: 1. at least 50 years of age at disease onset 2. new onset or new type of localized pain in the head 3. temporal artery abnormality (i.e., temporal artery tenderness to palpation or decreased pulsation unrelated to arteriosclerosis of cervical arteries) 4. esr of greater than 40 mm in the first hour by the westergren method 5. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells * corticoid treatment since less than 14 days * signed informed consent * affiliation to the social security system exclusion criteria: * dementia * predictable non observance * neoplasia since less than 5 years

Keywords: giant cell arteritis prednisone pharmacokinetics
no surgery trial / two dose-escalation strategies

Conditions: Stage II Rectal Cancer

Summary: a randomized study of 131 patients. patients with a clinical t2-3 n0 rectal cancer will be randomized to two arms (arm a: standard chemoradiation (45 gy in 25 with concomitant 5-fu or xeloda chemotherapy) and an external beam boost of 9 gy compared to arm b: standard chemoradiation (45 gy in 25 with concomitant 5-fu or xeloda chemotherapy) and followed by a brachytherapy boost of 30 gy in 3 fractions).

it is becoming clear that there is a now an international consensus that rectal cancer research efforts need to be more focused in optimizing a non-surgical approach. this concept is very relevant to an ageing patient population with multiple co-morbidities regularly seen at the jewish general hospital and across the province. after interim analysis on 40 patients of the pilot study a phase iii study is proposed. we are therefore proposing a phase iii multicentric study of 145 patients to compare the two best known radiation dose escalation strategies and to achieve a complete clinical response. patients with a clinical t2-3 n0-1 rectal cancer will be randomized to two arms (arm a: standard chemoradiation (45 gy in 25 with concomitant 5-fu or xeloda chemotherapy) and an external beam boost of 9 gy compared to arm b: standard chemoradiation (45 gy in 25 with concomitant 5-fu or xeloda chemotherapy) and followed by a brachytherapy boost of 30 gy in 3 fractions). patients that have a high risk of recurrence or with more advanced stages of the disease will be excluded from the study, as only the local disease is being treated. the primary outcome for this proposal is rectum preservation in treated patients.

Eligibility criteria:
inclusion criteria: * rectal cancer patients, clinically staged as t2-t3 by mri or endoscopic/trans-rectal ultrasound * rectal cancer staged as n0 by mri or eus/trus * no metastatic lesion * rectal tumor occupying less than half of the circumference * tumor less than 5 cm on its largest dimension * tumor located at less than 10 cm from the anal verge * tumor penetration less than 5 mm in the mesorectal fat * tumor accessible for brachytherapy * lumen accessible for colonoscopy * patient should be a suitable candidate for brachytherapy and chemotherapy * older than 18 years of age * adequate birth control measures in women of childbearing potential * written informed consent exclusion criteria: * patients with previous pelvic radiation * evidence of distant metastasis * extension of malignant disease to the anal canal * tumors staged as t4 * tumors larger than 5 cm in length
lipomas treated with subcutaneous injections of cooled sodium chloride

Conditions: Lipoma

Summary: lipomas are benign tumors composed of mature adipose tissue. while harmless, these are the most common type of soft tissue growths with some patients developing numerous lipomas. patients often seek removal for cosmesis, or symptoms caused by location and/or compression of surrounding structures. this exploratory study aims to evaluate the effectiveness of subcutaneous injections of cooled normal saline as a treatment option for lipomas. the study will assess whether this technique could serve as a viable alternative to existing treatment options, especially compared to topically applied fat-freezing devices. the investigators propose that this method may offer a more comfortable nonsurgical option for targeted fat reduction, as the cold temperatures are applied directly to the lipomas.


Eligibility criteria:
inclusion criteria: * at least one clinically diagnosed subcutaneous lipoma exclusion criteria: * unable to give informed consent * participant has a lipoma on the face * lipomas located subfascial or within deep tissue (e.g., intramuscular lipomas) * lipomas larger than 10 cm in diameter (fat deposits exceeding 500 ml in volume) * rapidly growing lipomas * lipomas exhibiting abnormal ultrasound findings (e.g., complex hyperechoic patterns, internal heterogeneity, or multilobulated appearance) * pregnant women
surgical and obstetric outcomes in patients with uterine malformations undergoing hysteroscopic corrective treatment

Conditions: Malformation; Female Infertility; Hysteroscopy Surgery

Summary: the goal of this observational cohort study is to learn if hysteroscopic correction can improve reproductive outcomes in women with uterine malformations. the main questions it aims to answer are: primary hypothesis: -does hysteroscopic correction significantly improve pregnancy rates at 12 months post-surgery in women with uterine malformations? secondary hypotheses: * does hysteroscopic correction significantly reduce the rate of first and second-trimester spontaneous abortions? * does hysteroscopic correction significantly increase the live birth rate? * in symptomatic patients, does hysteroscopic correction significantly reduce dyspareunia and dysmenorrhea? * which patient, histopathological, and surgical factors are associated with improved obstetric outcomes? researchers will compare obstetric outcomes (pregnancy rate, spontaneous abortion rate, live birth rate, and symptom severity) before and after hysteroscopic correction to determine the effectiveness of this surgical intervention. participants will be women with uterine malformations who underwent hysteroscopic correction at the digital hysteroscopy center of policlinico universitario a. gemelli di roma and azienda ospedaliera universitaria federico ii di napoli. data will be retrospectively collected and analyzed to assess the impact of surgery on reproductive outcomes.


Eligibility criteria:
inclusion criteria: * women who underwent hysteroscopy at the class hysteroscopy center of policlinico universitario a. gemelli di roma or azienda ospedaliera universitaria federico ii di napoli for the correction of uterine malformations, including partial, complete, and septate bicornuate uteri, dysmorphic uteri, with or without associated cervical and/or vaginal septa (eshre-esge classification: u1a and u1c; u2a, u2b, and u3c with or without associated cervical or vaginal anomalies c1/2 or v1/2). * age 18 years or older. exclusion criteria: * patients with known, concurrent causes of infertility. * patients who did not provide informed consent to participate in the study. * age younger than 18 years.

Keywords: uterine malformation hysteroscopic metroplasty reproductive outcomes
anti tnf α improves endothelial dysfunction in ibd patients

Conditions: Crohn's Disease

Summary: study hypothesis - this study will assess the presence of endothelial dysfunction in patients with crohn's disease before and after 12 weeks treatment of anti tnf α.

crohn's disease (cd) is a life long disease that mainly affects young adults. there is evidence that gut tissue injury is the result of an abnormal immune response that involved multiple non immune cellular systems including the intestinal microvascular endothelial cell. moreover, clinical studies have shown that 1-7% of irritable bowel disease (ibd) patients suffer from arterial and venous thromboembolic complication. chronic inflammation has a major role in the development and propagation of endothelial dysfunction, which can lead to coronary artery disease. endothelial dysfunction has been described in patients with various and diverse chronic inflammatory conditions. over the last few years, dysfunction of vascular endothelium has been widely recognized as the first step in the development of atherosclerosis. several inflammatory mediators, such as c-reactive protein (crp), tumor necrosis factor α, (tnf α), nitric oxide (no), vascular endothelial growth factor, cd-40, interleukin-6 (il-6), which are up-regulated in ibd, also are known to impact vascular impact. the normal endothelium produces a vasodilatatory response to ischemia referred to us as reactive hyperemia. shear stress on the blood vessel wall leads to the production and release vasodilatation. with endothelial dysfunction there is often either a blunted vasodilatatory in response to ischemic event, and chronic inflammation. the hypothesis of this study is that patients with crohn's disease have an increased incidence of endothelial dysfunction, which can be corrected or improved by treatment with anti tnf α. the purpose of our study was to assess endothelial function in patients with crohn's disease, before and after treatment (steroids, immunomodulators, and anti tnf α). this study assessed the presence of endothelial dysfunction in patients with crohn's disease and evaluated the possible role of tumor necrosis factor (tnf)-α in the pathophysiology of this abnormality. in this study we will preformed an endothelial function test before and after treatment by endopath device from itamar medical, fda approved. safety- each subject will be screened by clinical history, physical examination, electrocardiogram, chest x-ray, mantoux test (ppd), routine chemical analysis, and biomarkers. the study protocol has been approved by the local institutional review board.

Eligibility criteria:
inclusion criteria: * non smoker * no history of ihd or other known risk factors for ihd exclusion criteria: * patients who had been treated with anti tnf α 4 weeks before the study * as well as those who received corticosteroids within 1 week before the study. * dm, ihd, crf, smoker
hdl-c in cardiac syndrome x

Conditions: Cardiovascular Diseases; Heart Diseases; Myocardial Ischaemia; Unstable Angina; Microvascular Angina

Summary: high density lipoprotein cholesterol (hdl-c) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver\[10\]. hdl-c promotes endothelial generation of nitric oxide (no) and improves endothelial function and arterial vasoreactivity\[11\]. in several studies, lower hdl-c level was reported to be associated with increased coronary artery disease (cad) risk\[12-14\]. hdl-c also has anti- inflammatory and anti-oxidant activities\[15,16\]. concerning anti-inflammatory activity, hdl-c inhibits the activation of monocytes/macrophages and neutrophils\[17,18\] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (vcam-1) and e-selectin\[15\]. in this study we aimed to investigate the relation of hdl-c level with systemic inflammatory markers in patients with cardiac syndrome x (csx).


Eligibility criteria:
inclusion criteria: * must be able to get exercise stress test * must be able to have coronary angiography * clinical diagnosis of typical anginaduring rest or effort * abnormal test result for exercise ecg or myocardial perfusion scintigraphy * must have of angiographically normal epicardial coronary arteries exclusion criteria: * patients with valvular heart disease (mitral stenosis and moderate to severe mitral regurgitation * patients with moderate to severe aortic stenosis and regurgitation including mitral annular calcification) * patients with heart failure (left ventricular ejection fraction \<50%) * patients with congenital heart disease, cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy * patients with cardiac surgery * patients with thyroid disease * patients with anemia * patients with pulmonary diseases * patients with infectious diseases (locally or systemic)

Keywords: cardiac syndrome x inflammation dyslipidemia
systematic evaluation of predictors of quality of life in the long-term after solid organ transplantation

Conditions: Organ Transplantation; Anxiety; Depression

Summary: a systematic evaluation of predictors of health related quality of life (hrqol) leads to multiple level of data analysis. the aim of the herein described observational project is to create a transplant patients registry on psychosocial outcomes and to evaluate longitudinally predictors of hrqol after different types of solid organ transplantation in the long-term. a sample size of 700 participants consisting of all solid organ types is envisioned. data will be compared with published healthy normative data. data evaluation of predictors of hrqol may guide development of tailored interventions to reduce complications and to further improve outcomes.


Eligibility criteria:
inclusion criteria: * follow-up at our outpatient clinics * written informed consent * sufficient german language skills to read and answer a battery of questionnaires * min 18 years exclusion criteria: * illiteracy

Keywords: quality of life adverse effects
the real world study of orelabrutinib in the treatment of cll/sll

Conditions: CLL/SLL

Summary: this is a multicenter, retrospective real-world study of orelabrutinib in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in china

orelabrutinib is a novel btk inhibitor with high selectivity and has been approved in china for relapsed/refractory cll/sll,, the purpose of this study is to describe the effectiveness and safety of orelabrutinib of chronic lymphocytic leukemia (cll) in real world.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old 2. patients with a definite diagnosis of cll/sll 3. prior or current use of orelabrutinib for ≥3 months 4. at least one follow-up was recorded during orelabrutinib treatment exclusion criteria: 1.patients who received orelabrutinib in a prospective clinical trial
efficacy study of a low volume of water intake and mosapride for endoscopy in patients with subtotal gastrectomy

Conditions: Foreign Body Left During Endoscopic Examination

Summary: a low volume of water intake and mosapride will effectively reduce food residue in remnant stomach for patients who had undergone subtotal gastrectomy due to gastric cancer.

we evaluate that a 500ml of water intake and mosapride will effectively reduce food residue in remnant stomach for patients who had undergone subtotal gastrectomy due to gastric cancer. we plan to compare this method with routine midnight fasting method for endoscopy in patients with subtotal gastrectomy.

Eligibility criteria:
inclusion criteria: * outpatients who had subtotal gastrectomy for gastric cancer exclusion criteria: * pregnancy * lactation * history of anastomotic stricture * recurrent advanced gastric cancer * poor general condition( \> 2 ecog) * other disseminated malignancy * significant renal failure or congestive heart failure (chf) * liver failure

Keywords: endoscopy gastrectomy stomach neoplasms
artesunate ointment for the treatment of anal hsil in hiv-negative participants

Conditions: Anal High-grade Squamous Intraepithelial Lesion; Anal HSIL; Anal HPV Infection; AIN

Summary: this is a phase ii double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of hiv-negative men and women who have anal high grade squamous intraepithelial lesions (anal hsil)

eligible participants in this study are randomized 2:1 to receive either artesunate or placebo ointment for the treatment of anal hsil. both groups receive four 5-day cycles of ointment, at weeks 0, 2, 4, and 6. participants are followed closely with anoscopy or high resolution anoscopy (hra) at weeks 8, 18, 30, and 42. after the week 18 hra visit, participants who have at least partial response will be followed with hra at week 30. participants who are found to be non-responders at week 18 will undergo standard of care ablation. participants who are found to have anal hsil at weeks 30 or 42 will be followed according to standard of care procedures. primary objective: to evaluate the complete and partial histopathologic response to four 5-day cycles of artesunate ointment in adult patients with biopsy-proven hpv-associated intra-anal hsil (18 weeks). secondary objectives: efficacy: to evaluate the viral clearance after four 5-day cycles of artesunate ointment to evaluate complete and partial intra-anal response to evaluate complete and partial peri-anal response to evaluate persistence of response throughout the study window safety: to evaluate the safety of artesunate ointment for the treatment of intra-anal hsil.

Eligibility criteria:
inclusion criteria: * adult men and women age ≥ 18 years * capable of informed consent * biopsy-confirmed intra-anal high-grade dysplasia (ain 2, ain 3, anal hsil) by hra. * positive anal human papillomavirus (hpv) test. * women of childbearing potential agree to use birth control for the duration of the study. * laboratory values at screening of: 1. serum alanine transaminase (sgpt/alt) \< 5 x upper limit of normal (uln) 2. serum aspartate transaminase (sgot/ast) \< 5 x uln 3. serum bilirubin (total) \< 2.5 x uln 4. serum creatinine ≤ 1.5 x uln * electrocardiogram (ecg) with no clinically significant findings as assessed by the investigator. * weight ≥ 50kg exclusion criteria: * pregnant and nursing women * diagnosis of low-grade anal dysplasia (ain 1, lsil), without the concomitant diagnosis of anal hsil, by hra * concurrent anal, vulvar, cervical, or penile cancer * hiv-seropositivity * currently receiving systemic chemotherapy or radiation therapy for another cancer. * patients who are on medical treatment with systemic immunosuppressants or steroids (e.g., active autoimmune disease). participants using nasal steroid treatments for allergic conditions may participate in the study. * concomitant use of strong ugt (uridine-diphosphate-glucuronosyltransferase) inhibitors * concomitant use of imiquimod or 5-fluorouracil (5-fu) for the duration of the study

Keywords: intra-anal topical non-surgical
body scan activity on bone marrow transplant patients and their caregivers

Conditions: Hematological Malignancy

Summary: this study will address whether teaching the body scan exercise to cancer patients with hematological malignancies and their caregivers during an inpatient hospitalization improves reported physical and psychological symptoms after a two-week period. giving patients and caregivers the opportunity to learn mindfulness and the tools to practice on their own is expected to lead to a decrease in stress and anxiety, and help empower patients and caregivers to better cope with stress in the future.


Eligibility criteria:
inclusion criteria: * voluntary \& self-selected patients and caregivers * located on the leukemia/lymphoma/bone marrow transplant floor at barnes jewish hospital exclusion criteria: -patients requiring a language translator or interpreter will be excluded from the study
a registry based study evaluating overall survival and treatment length in mcrpc patients treated with enzalutamide in sweden

Conditions: Metastatic Castration Resistant Prostate Cancer

Summary: the purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mcrpc) patients. the primary purpose is to evaluate overall survival (os) in mcrpc patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel) (post chemo patients). this study will also evaluate treatment duration with enzalutamide in patients pre- and post-chemo.

the data source in this study is a local hospital registry created from a patient follow up of prostate cancer patients.

Eligibility criteria:
inclusion criteria: * chemo naïve mcrpc patients treated with enzalutamide and ongoing androgen deprivation therapy with a gonadotropin releasing hormone (gnrh) analogue or orchiectomy (i.e., surgical or medical castration). * mcrpc patients treated with enzalutamide and ongoing androgen deprivation therapy with a gonadotropin releasing hormone (gnrh) analogue or orchiectomy (i.e., surgical or medical castration) post chemo. exclusion criteria * mcrpc patients previously exposed to radium-223, abiraterone acetate and/or cabazitaxel for mcrpc (pre- and post chemotherapy). * patients previously exposed to chemotherapy or abiraterone acetate+prednisolone in combination with gnrh analogue for hormone sensitive prostate cancer (hspc).

Keywords: enzalutamide metastatic castration-resistant prostate cancer xtandi registry based study mdv3100 mcrpc